• Hub Login
  • Contact
  • Investors
  • Viveve Solutions
    • Viveve System
    • InControl by Viveve
  • Clinical Studies
  • About
    • Mission
    • Leadership
    • Careers
  • News
    • Blog
    • Media & Press
    • Investor News
    • Events
  • Testimonials
Select Page
Dev Site

A Global Women’s Intimate Health Company

Press Releases

Investors
  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Publications
    • IR Calendar
    • Analyst Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Clinical Advisory Board
    • Medical Consultants
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Investor Presentation
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Publications
  • IR Calendar
  • Analyst Coverage
  • Email Alerts

Viveve to Host Conference Call to Provide Corporate Update and Year-End 2019 Financial Results on March 19, 2020

Mar 6, 2020

Viveve Completes Enrollment in Short-Term Feasibility Study for Stress Urinary Incontinence

Mar 4, 2020

Viveve Initiates Enrollment of its Short-Term Feasibility Study in Stress Urinary Incontinence

Jan 14, 2020

Viveve Announces Compliance with Nasdaq Listing Rules

Dec 31, 2019

Viveve Announces Authorization to Initiate Short-Term Feasibility Study in Stress Urinary Incontinence from Canadian Ministry of Health

Dec 18, 2019

Viveve Announces Clearance of Next Generation 2.0 System in South Korea

Dec 10, 2019

Viveve Announces Launch of Viveve 2.0 System in China

Dec 3, 2019

Viveve Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Nov 26, 2019

Viveve Announces Pricing of $10 Million Underwritten Public Offering

Nov 22, 2019

Viveve Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 7, 2019
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...30

    Solutions

    • Viveve System
    • InControl Products
    • Common Conditions

    About

    • Mission
    • Leadership
    • Contact Us
    • Investor Information

    News

    • Viveve Blog
    • Events
    • News & Publications
    • Testimonials

    Resources

    • Hub Login
    • Careers with Viveve
    • Support Center
    Dev Site
    345 Inverness Drive South • Building B, Suite 250 • Englewood, CO 80112
    The Viveve® System is an internationally patented cryogen-cooled, monopolar radiofrequency (CMRF) energy-based device. It has received regulatory approvals and clearances in many countries throughout the world and is available through physician import license in Japan. Country-specific approved indications include: • In Argentina the Viveve System is indicated for the treatment of urinary incontinence, vaginal laxity, and sexual function. • In Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, Hong Kong, Japan, Mexico, Panama, Philippines, Singapore, Uruguay, and Venezuela the Viveve System is indicated for the treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function. • In the EU, Bahrain, Iceland, Korea, Kuwait, Lebanon, Liechtenstein, Norway, South Africa, Switzerland, and Ukraine the Viveve System is indicated for the treatment of vaginal laxity. • In Peru, Taiwan, and the United States the Viveve System is cleared for general surgical procedures for electrocoagulation and hemostasis.